DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Rowland A, Dias MM, Wiese MD. et al.
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Br J Cancer 2015;
112: 1888-1894
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.